Why Gilead Sciences Investors Shouldn't Give Up on Remdesivir Just Yet
Shares of Gilead Sciences (NASDAQ: GILD) are up a modest 8% over the past year, while the S&P 500 has risen by 29% and COVID-19 vaccine maker Moderna (NASDAQ: MRNA) has soared 385%. Stocks of companies treating COVID haven't been as popular as shares of vaccine makers, since the focus has been on getting as many individuals vaccinated as possible, and the government has put in orders for millions of doses.
But COVID still isn't going away, and that could make Gilead an underrated healthcare stock to buy right now. Its antiviral drug remdesivir is currently approved for use in hospitals to treat the disease, and it could play a much bigger role in the future, as a recent study suggests that it could be effective if used early on.
Image source: Getty Images.
Source Fool.com
